Drug Trial Radar · NCT03824587
Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy
Last checked: Nov 19, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
236
Actual
Start
Feb 28, 2019
Primary completion
Jul 17, 2019
Study completion Jul 17, 2019
Sponsor
- Lead sponsor
- ArdelyxIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study to evaluate the effect of tenapanor on change in s-P levels when tenapanor is administered orally, twice daily for 28 days as adjunctive therapy to ESRD subjects with hyperphosphatemia on stable phosphate binder therapy.
Conditions
- Hyperphosphatemia
Interventions
TenapanorDrug
Active Drug
PlaceboDrug
Inactive Drug
Phosphate Binder AgentsDrug
standard of care phosphate binder use at study entry was maintained throughout the entire study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Serum Phosphorus (s-P) Level From Baseline to Week 4.Time frame: 4 Weeks (28 days randomization period; from baseline to week 4)
Locations
48 sites in 1 country. Site status is shown where the registry gives one.
Nephrology Consultants, LLC
Huntsville, Alabama
US Renal Care Pine Bluff
Pine Bluff, Arkansas
Southeast Renal Research
Beverly Hills, California
California Institute of Renal Research - Chula Vista
Chula Vista, California
North America Research Institute
Lynwood, California
DaVita Clinical Research - Santa Fe Spring
Montebello, California
Central Coast Nephrology
Salinas, California
North America Research Institute - San Dimas
San Dimas, California
Chabot Nephrology Medical Group
Union City, California
American Institute of Research
Whittier, California
Nova Clinical Research, LLC
Bradenton, Florida
Horizon Research Group - Coral Gables
Coral Gables, Florida
South Florida Research Institute
Lauderdale Lakes, Florida
Total Research Group, LLC
Miami, Florida
Omega Research Consultants, LLC
Orlando, Florida
Genesis Clinical Trials
Tampa, Florida
Dialysis Clinic, Inc - Albany GA
Albany, Georgia
Boise Kidney & Hypertension, PLLC - Meridian
Caldwell, Idaho
Renal Associates of Baton Rouge
Baton Rouge, Louisiana
Dialysis Clinic, Inc - Boston/Somerville
Boston, Massachusetts
Paragon Health PC - Nephrology Center
Kalamazoo, Michigan
InterMed Consultants
Minneapolis, Minnesota
Nephrology and Hypertension Associates, LTD
Tupelo, Mississippi
Clinical Research Consultants, LLC
Kansas City, Missouri
Dialysis Clinic, Inc - Kansas City
Kansas City, Missouri
Polack Renal, LLC (SMO)
St Louis, Missouri
Kidney Specialists of Southern Nevada
Las Vegas, Nevada
Sierra Nevada Nephrology Consultants
Reno, Nevada
Dialysis Clinic, Inc - North Brunswick
North Brunswick, New Jersey
Renal Medicine Associates
Albuquerque, New Mexico
U.S. Renal Care - Gallup
Gallup, New Mexico
Northwell Health
Great Neck, New York
Mountain Kidney and Hypertension Associates
Asheville, North Carolina
Mountain Kidney & Hypertension Associates, P.A.
Asheville, North Carolina
Durham Nephrology Associates
Durham, North Carolina
Southeastern Nephrology Associates - Wilmington
Wilmington, North Carolina
University of Cincinnati (UC) - Department of Nephrology
Cincinnati, Ohio
Northeast Clinical Research Center
Bethlehem, Pennsylvania
Columbia Nephrology Associates, P.A.
Columbia, South Carolina
South Carolina Nephrology & Hypertension Center Inc.
Orangeburg, South Carolina
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.